OhSay, I'm with you. The lack of transparency is disturbing. So let's play the speculation game:
What if no changes were made to the mono vs. plus patients, and the results were heading up on an average as was presented? They switch from calling the sub group "Mono" to calling it "strong performers". What if the strong performers were not the "Mono" group? Would that be a reason to not disclose any trail changes? To what end...why not be specific?
News 
Market Data 
Discover 
